Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.31 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.31 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.31 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.31 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.31 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.31 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.31 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.31 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.31 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.31 |
| ▸ | PSMA8 | Q8TAA3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12023453 | 1.00 | CTSB (0.42) | CTSBCTSSPSMB11PSMA7PSMB1 | |
| SCHEMBL12040461 | 1.00 | CTSB (0.42) | CTSBCTSSPSMB11PSMA7PSMB1 | |
| SCHEMBL11929776 | 0.89 | CTSB (0.44) | CTSBCTSSPSMB11PSMA7PSMB1 | |
| SCHEMBL15159923 | 0.88 | CTSB (0.44) | CTSBCTSS | |
| SCHEMBL13502724 | 0.86 | CTSB (0.39) | CTSBCTSS | |
| SCHEMBL16510294 | 0.85 | CTSB (0.47) | CTSBCTSS | |
| SCHEMBL8171020 | 0.84 | CTSB (0.56) | CTSBCTSS | |
| SCHEMBL12023508 | 0.84 | CTSB (0.56) | CTSBCTSS | |
| SCHEMBL12023459 | 0.84 | CTSB (0.56) | CTSBCTSS | |
| SCHEMBL12658472 | 0.84 | CTSB (0.56) | CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | CTSB 372/4885CTSS 942/4885PSMB11 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.